TMC6 Is a Novel Therapeutic Target for Pathogenic Cardiac Hypertrophy
TMC6 is an endogenous brake on pathological hypertrophy that restrains CIB1-calcineurin/NFAT signaling via endoplasmic reticulum sequestration of CIB1. Restoring full-length TMC6 mitigates pressure-overload remodeling, nominating the TMC6-CIB1 axis as a therapeutic target.
Authors
- Wenpu Guo
- Hangping Fan
- Jiaxi Shen (ORCID: https://orcid.org/0000-0001-6540-8283)
- Y Tang
- Tingyu Gong
- Jinghai Chen
- Birou Zhong
- Zongkuai Yang
- Hangyuan Qiu
- Dandan Liu (ORCID: https://orcid.org/0000-0002-1480-0290)
- Hong Ma (ORCID: https://orcid.org/0000-0001-7222-7376)
- Xiaozhi Fan
- Xiaoxuan Dong
- Xiaoting Zhang
- Yuhong Cao
- Feng Gao
- Ziwei Pan
- Yange Wang
- Ping Liang
- Hongkun Wang
Institutions
- Allen Institute for Brain Science (US)
- Fudan University (CN)
- Sir Run Run Shaw Hospital (CN)
- Eye & ENT Hospital of Fudan University (CN)
- Zhejiang Shuren University (CN)
- Institute of High Energy Physics (AT)
- Second Affiliated Hospital of Zhejiang University (CN)
- Ministry of Public Health (MG)
Publication Details
- Journal
- Circulation Research
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1161/circresaha.125.327680
- Citations
- 1
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 30.07